CLAIMS AS ALLOWED - WITH AMENDMENTS UNDER 37 C.F.R. §1.312

U.S. Appln. Ser. No. 09/943,334

28. (PREVIOUSLY PRESENTED) A method for treating or preventing atherosclerosis in a human or animal comprising administering to said human or animal an antigenic vaccine peptide comprising a universal helper T cell epitope portion linked to a B cell epitope portion, wherein said B cell epitope portion comprises a B cell epitope of CETP.

29. (PREVIOUSLY PRESENTED) The method according to claim 28, wherein said helper T cell epitope portion comprises a helper T cell epitope derived from an antigenic peptide selected from the group consisting of tetanus toxoid, diphtheria toxoid, pertussis vaccine, Bacile Calmette-Guerin (BCG), polio vaccine, measles vaccine, mumps vaccine, rubella vaccine, purified protein derivative of tuberculin, keyhole limpet hemocyanin, hsp70, and combinations thereof.

37. (PREVIOUSLY PRESENTED) The method according to claim 28, wherein said B cell epitope portion of the antigenic vaccine peptide comprises 6 to 26 consecutive amino acids of the carboxyl terminal 26 amino acids of human cholesteryl ester transfer protein (SEQ ID NO:1).

38. (PREVIOUSLY PRESENTED) The method according to claim 37, wherein the vaccine peptide comprises the amino acid sequence of SEQ ID NO:2.

39. (PREVIOUSLY PRESENTED) The method according to claim 37, wherein the vaccine peptide comprises a dimer of the amino acid sequence of SEQ ID NO:2.

40. (NEW) The method according to Claim 28, wherein the mode of said administration of said antigenic vaccine peptide is selected from the group consisting of intraperitoneal administration, interperitoneal administration, intramuscular injection, intravenous injection, subcutaneous injection, and oral administration.

41. (NEW) The method according to Claim 40, wherein said administration is comprised of one primary dose of said antigenic vaccine peptide followed by one or more booster administrations of said vaccine peptide.

42. (NEW) The method according to Claim 28, wherein said antigenic vaccine peptide is formulated with a pharmaceutically acceptable adjuvant.

43. (NEW) The method according to Claim 42, wherein said pharmaceutically acceptable adjuvant is alum.

44. (NEW) The method according to Claim 28, wherein said antigenic vaccine peptide further comprises an amino and/or carboxyl terminal cysteine residue.